JP2022106920A5 - - Google Patents

Download PDF

Info

Publication number
JP2022106920A5
JP2022106920A5 JP2022076713A JP2022076713A JP2022106920A5 JP 2022106920 A5 JP2022106920 A5 JP 2022106920A5 JP 2022076713 A JP2022076713 A JP 2022076713A JP 2022076713 A JP2022076713 A JP 2022076713A JP 2022106920 A5 JP2022106920 A5 JP 2022106920A5
Authority
JP
Japan
Prior art keywords
aryl
methyl
alkyl
alkoxy
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022076713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022106920A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/030080 external-priority patent/WO2017189978A1/en
Application filed filed Critical
Publication of JP2022106920A publication Critical patent/JP2022106920A/ja
Publication of JP2022106920A5 publication Critical patent/JP2022106920A5/ja
Priority to JP2023215791A priority Critical patent/JP2024038012A/ja
Pending legal-status Critical Current

Links

JP2022076713A 2016-04-28 2022-05-06 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 Pending JP2022106920A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023215791A JP2024038012A (ja) 2016-04-28 2023-12-21 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662328857P 2016-04-28 2016-04-28
US62/328,857 2016-04-28
PCT/US2017/030080 WO2017189978A1 (en) 2016-04-28 2017-04-28 Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2018556819A JP7129703B2 (ja) 2016-04-28 2017-04-28 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018556819A Division JP7129703B2 (ja) 2016-04-28 2017-04-28 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023215791A Division JP2024038012A (ja) 2016-04-28 2023-12-21 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Publications (2)

Publication Number Publication Date
JP2022106920A JP2022106920A (ja) 2022-07-20
JP2022106920A5 true JP2022106920A5 (OSRAM) 2023-02-07

Family

ID=60160145

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018556819A Active JP7129703B2 (ja) 2016-04-28 2017-04-28 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
JP2022076713A Pending JP2022106920A (ja) 2016-04-28 2022-05-06 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
JP2023215791A Pending JP2024038012A (ja) 2016-04-28 2023-12-21 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018556819A Active JP7129703B2 (ja) 2016-04-28 2017-04-28 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023215791A Pending JP2024038012A (ja) 2016-04-28 2023-12-21 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Country Status (7)

Country Link
US (2) US11192914B2 (OSRAM)
EP (1) EP3448392A4 (OSRAM)
JP (3) JP7129703B2 (OSRAM)
CN (1) CN109689063A (OSRAM)
CA (1) CA3022119A1 (OSRAM)
EA (1) EA201892448A1 (OSRAM)
WO (1) WO2017189978A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3022119A1 (en) * 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2023521425A (ja) * 2020-04-14 2023-05-24 ヤンセン ファーマシューティカルズ,インコーポレーテッド E型肝炎の治療のためのアルキニルヌクレオシド類似体
US11357865B2 (en) 2020-04-27 2022-06-14 Sixfold Bioscience Ltd. Compositions containing nucleic acid nanoparticles with modular functionality
CN112279877B (zh) * 2020-12-15 2021-08-06 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法
CN113621013B (zh) * 2021-09-17 2023-07-21 中国人民解放军军事科学院军事医学研究院 2`-乙炔基腺苷磷酰胺类衍生物及其制备方法和用途
CN117567310A (zh) * 2023-11-28 2024-02-20 重庆智合生物医药有限公司 一种神经酰胺np1的合成方法

Family Cites Families (447)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607925A (en) * 1988-11-15 1997-03-04 Merrell Pharmaceuticals Inc. Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
UA6419A1 (uk) 1991-01-03 1994-12-29 Чеслав-Констянтин Альбінович Будревич Вітродвигун будревича
EP0627930A4 (en) 1992-07-13 1997-08-20 Kenneth E Sherman COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US6107027A (en) 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
GB9605293D0 (en) 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
WO1998019670A2 (en) 1996-11-01 1998-05-14 Thomas Najarian Combination therapy of hepatitis c infections
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
US6103706A (en) 1997-04-29 2000-08-15 New York Blood Center, Inc. Methods for treating viral infections
US6010890A (en) 1997-04-29 2000-01-04 New York Blood Center, Inc. Method for viral inactivation and compositions for use in same
US6143752A (en) 1997-08-01 2000-11-07 Oren; Ran Method for preventing or arresting liver damage in humans
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
ES2186660T3 (es) 1997-09-21 2003-05-16 Schering Corp Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
WO1999018993A1 (en) 1997-10-13 1999-04-22 Otsuka Pharmaceutical Co., Ltd. Ameliorant for hepatitis c remedial effect and application thereof
FR2771637B1 (fr) 1997-12-01 2003-10-24 Hutchinson Utilisation d'un halogenure de dialkyldialkylammonium par voie parenterale dans les infections bacteriennes et virales
US6465487B1 (en) 1997-12-11 2002-10-15 Synergy Pharmaceuticals, Inc. Inhibition of membrane-associated viral replication
AU1703799A (en) 1997-12-17 1999-07-05 Cornell Research Foundation Inc. Cyclooxygenase-2 inhibition
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
WO1999041266A1 (en) 1998-02-12 1999-08-19 Emory University Sphingolipid derivatives and their methods of use
WO1999049873A1 (en) 1998-03-27 1999-10-07 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
JP2000007578A (ja) 1998-06-24 2000-01-11 Hiroaki Okushin C型肝炎ウイルスの陰性化のための投薬システム
AU759480B2 (en) 1998-07-01 2003-04-17 Debiopharm S.A. Novel cyclosporin with improved activity profile
RU2158604C2 (ru) 1998-07-03 2000-11-10 Толоконская Наталья Петровна Способ лечения вирусного гепатита c
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
ES2229820T3 (es) 1998-10-16 2005-04-16 Schering Corporation Terapia de combinacion ribavirina-interferon alfa para erradicar el hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
US20080275005A1 (en) 1998-11-25 2008-11-06 Murphy Michael P Mitochondrially targeted antioxidants
US6824768B2 (en) 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
WO2000037097A1 (en) 1998-12-18 2000-06-29 Schering Corporation Ribavirin-interferon alfa induction hcv combination therapy
AR021876A1 (es) 1998-12-18 2002-08-07 Schering Corp Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
JP2000212099A (ja) 1999-01-19 2000-08-02 Mochida Pharmaceut Co Ltd ウイルス性肝炎治療剤
RU2001125094A (ru) 1999-02-13 2003-09-27 Пьюрпалс Текнолоджиз, Инк. (Us) Способы инактивации патогенов с использованием импульсного света широкого спектра
JP2002541204A (ja) 1999-04-12 2002-12-03 ユニバーシティ オブ マドラス B型肝炎、c型肝炎及びその他の肝臓の関連ウイルス感染の治療に有用な医薬製剤及びその調製方法
US6849254B1 (en) 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
WO2002038105A2 (en) 2000-11-08 2002-05-16 Slil Biomedical Corporation Novel polyamine analog-amino acid conjugates useful as anticancer agents
HK1053126A1 (zh) 1999-07-22 2003-10-10 新生物生物公司 酶催化的治疗活化
RU2002105485A (ru) 1999-08-13 2004-01-27 Ф.Хоффманн-Ля Рош Аг (Ch) Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α)
US20050245502A1 (en) 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
KR100392292B1 (ko) 2000-01-07 2003-07-22 주식회사 펩트론 5원환 융합 방향족 헤테로사이클릭 화합물을 유효성분으로 하는 hcv 치료제 조성물
AU2001253206A1 (en) 2000-04-05 2001-10-23 Tularik, Inc. Ns5b hcv polymerase inhibitors
US7018796B2 (en) 2000-04-07 2006-03-28 Shionogi & Co., Ltd. Preincubation assay methods
DE60135366D1 (de) 2000-04-18 2008-09-25 Virco Bvba Methode zur bestimmung der resistenz gegen medikamente
US6415797B1 (en) 2000-07-07 2002-07-09 First Circle Medical, Inc. Treatment of human herpesviruses using hyperthermia
SI1385870T1 (sl) 2000-07-21 2010-08-31 Schering Corp Peptidi kot NS3-serin proteazni inhibitorji virusa hepatitisa C
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
RO118842B1 (ro) 2000-08-02 2003-12-30 Cristian Paul Munteanu Metodă de tratament a limfoamelor maligne nonhodgkin de mică malignitate, asociate cu boală cronică de ficat de etiologie virală c
WO2002010743A1 (en) 2000-08-02 2002-02-07 Ortho-Mcneil Pharmaceutical, Inc. Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1430903A1 (de) 2000-10-12 2004-06-23 Viromics Gmbh Verwendung von Proteasome Hemmern zur Behandlung von Virus-Infektionen
IL155414A0 (en) 2000-10-13 2003-11-23 Univ Monash Disease prevention by reactivation of the thymus
HK1052878A1 (zh) 2000-10-18 2003-10-03 Schering Corporation 利巴传林-聚乙二醇化干扰素α:丙型肝炎病毒的联合治疗
FR2815543B1 (fr) 2000-10-19 2003-10-24 Sedat Seringue d'auto-injection d'un melange extemporane
AU2002243443A1 (en) 2000-10-20 2002-07-24 Genetics Institute, Llc Method and composition for inhibition of tumor growth and enhancing an immune response
WO2002053096A2 (en) 2000-12-06 2002-07-11 The Trustees Of The University Of Pennsylvania Single therapy and combination therapy involving drugs with target cellular proteins and drugs which target pathogen-encoded proteins
SK286630B6 (sk) 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
US6673775B2 (en) 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US7326536B2 (en) 2001-05-03 2008-02-05 Eli Lilly And Company Agents for treatment of HCV and methods of use
US6833351B2 (en) 2001-05-21 2004-12-21 Douglas T. Dieterich Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
WO2003002152A2 (en) 2001-06-29 2003-01-09 Maxygen Aps Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
WO2003007981A1 (en) 2001-07-20 2003-01-30 Intermune, Inc. Methods of treating liver fibrosis
WO2003024461A1 (en) 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
JP2005508926A (ja) 2001-09-28 2005-04-07 インターミューン インコーポレイテッド 治療失敗例の患者においてc型肝炎ウイルス感染を治療するための方法
PL369129A1 (en) 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
US20050063949A1 (en) 2001-10-05 2005-03-24 Gary Visor Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
PE20030545A1 (es) 2001-10-31 2003-06-19 Schering Corp Formulaciones de jarabe de ribavirina
WO2003037908A1 (en) 2001-10-31 2003-05-08 Ribapharm Inc. Antiviral combination therapy and compositions
JP2005536982A (ja) 2001-11-07 2005-12-08 麒麟麦酒株式会社 インビトロにおけるt細胞増幅および増幅されたt細胞集団
AUPR879601A0 (en) 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
JP2005517648A (ja) 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法
DE60221627D1 (de) 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
US6906190B2 (en) 2002-01-04 2005-06-14 Ribapharm Inc. Inhibitors for de novo-RNA polymerases and methods of identifying targets for same
RU2212248C1 (ru) 2002-01-21 2003-09-20 Государственное образовательное учреждение высшего профессионального образования Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Способ лечения больных хроническим вирусным гепатитом c
AU2003217747A1 (en) 2002-02-26 2003-09-09 North Shore-Long Island Jewish Research Insitute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
CA2383243A1 (en) 2002-04-23 2003-10-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for inhibiting fibrogenesis
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2003101199A1 (en) 2002-05-31 2003-12-11 Schering Corporation Combination therapy for rna virus infections involving ribavirin and impdh inhibitors
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
ITMI20021860A1 (it) 2002-08-28 2004-02-29 Scalia Antonio Cassar Impiego dei triptani come agenti antivirali.
WO2004039996A1 (en) 2002-11-01 2004-05-13 Cadila Healthcare Limited Mthod for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris
US7902203B2 (en) 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
AU2003287666A1 (en) 2002-11-13 2004-06-03 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
AU2003295773A1 (en) 2002-11-21 2004-06-18 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
WO2004073599A2 (en) 2003-02-18 2004-09-02 Pfizer Inc. Inhibitors of hepatitis c virus, compositions and treatments using the same
EP1601368A2 (en) 2003-02-28 2005-12-07 Intermune, Inc. Methods and compositions for treatment of viral diseases
WO2004078127A2 (en) 2003-02-28 2004-09-16 Intermune, Inc. Continuous delivery methods for treating hepatitis virus infection
AU2003225670A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
TWI269656B (en) 2003-03-05 2007-01-01 Original Image Co Ltd Therapeutical composition for hepatitis C
UA64191A (en) 2003-03-14 2004-02-16 Yevhenii Mykhailovych Neiko Method for treating chronic hepatitises of various etiology
US20040198840A1 (en) 2003-04-02 2004-10-07 Deloach Reuben Edwin Hydrazide substrate safely shuts down disease activated protease to halt viral replication, cancerous cell division, and toxic protein generation
EP2033654B1 (en) 2003-04-16 2012-05-16 Bristol-Myers Squibb Company Process for resolving a mixture of alkyl ester enantiomers using an enzyme
US20040258663A1 (en) 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
WO2005000308A2 (en) 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
ES2297424T3 (es) 2003-05-21 2008-05-01 Boehringer Ingelheim International Gmbh Compuestos inhibidores de la hepatitis c.
EP2345659A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US20050187170A1 (en) 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
AU2004249280A1 (en) 2003-06-20 2004-12-29 Viral Genomix, Inc. Antiviral compositions and methods of using the same
WO2005010143A2 (en) 2003-07-11 2005-02-03 Oregon Health And Science University Methods of treatment and disgnosis using modulators of virus-induced cellular gene sequences
MD2549G2 (ro) 2003-07-18 2005-08-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Metodă de tratament a hepatitei virale cronice C.
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2005018330A1 (en) 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
WO2005025583A2 (en) 2003-09-05 2005-03-24 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
US20070110714A1 (en) 2003-09-08 2007-05-17 Norio Hayashi Medicinal composition for treatment of chronic hepatitis c
AR045870A1 (es) 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
OA13315A (en) 2003-10-14 2007-04-13 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
WO2005038056A1 (en) 2003-10-14 2005-04-28 Intermune, Inc. Combination therapy for the treatment of viral diseases
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US20050085528A1 (en) 2003-10-17 2005-04-21 Pfizer Inc. Parmaceutical
ATE490470T1 (de) 2003-10-24 2010-12-15 Immunaid Pty Ltd Therapieverfahren
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
EP1677827B1 (en) 2003-10-27 2008-12-10 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
UA68233A (en) 2003-11-25 2004-07-15 Univ Zaporizhia State Medical Method for treating chronic hepatitis c
US7078064B2 (en) 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
JP4970048B2 (ja) 2003-12-22 2012-07-04 カトリーケ・ウニフェルジテイト・ルーベン・カー・イュー・ルーベン・アール・アンド・ディ イミダゾ[4,5−c]ピリジン化合物および抗ウイルス治療の方法
WO2005067963A1 (en) 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
US20070258946A1 (en) 2003-12-23 2007-11-08 Blatt Lawrence M Combination Therapy for Treating Hepatitis C Virus Infection
WO2005062949A2 (en) 2003-12-23 2005-07-14 Intermune, Inc. Method for treating hepatitis virus infection
DE10361944A1 (de) 2003-12-31 2005-07-28 Viromics Gmbh Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung
US20080234182A1 (en) 2007-03-22 2008-09-25 Innovative Biologics, Inc. Blockers of pore-forming virulence factors and their use as anti-infectives
WO2006003521A1 (en) 2004-02-06 2006-01-12 Monash University High dose, short interval use of sulfated polysaccharides for the treatment of infections
WO2005085275A1 (en) 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis c virus ns3 protease
WO2005102353A1 (en) 2004-04-22 2005-11-03 Howard J Smith & Associates Pty Ltd Supportive treatment of liver disease
CA2564503C (en) 2004-05-04 2015-12-29 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of mir-122 in hepatitis c virus infected subjects and cells
CA2565658A1 (en) 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
AR049635A1 (es) 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
WO2006016930A2 (en) 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
WO2005116054A1 (en) 2004-05-25 2005-12-08 Boehringer Ingelheim International, Gmbh Process for preparing acyclic hcv protease inhibitors
EP1765283A4 (en) 2004-06-08 2012-11-28 Vertex Pharma PHARMACEUTICAL COMPOSITIONS
ATE497775T1 (de) 2004-07-14 2011-02-15 Novartis Pharma Gmbh Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
EP1627641A1 (en) 2004-08-04 2006-02-22 Victor Eluwa Pharmaceutical compositions comprising metal oxides and uses thereof
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
AU2005289453A1 (en) 2004-09-27 2006-04-06 Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health Modulating MxA expression
HRP20110169T1 (hr) 2004-10-01 2011-04-30 Debiopharm S.A. Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c
JP2008514723A (ja) 2004-10-01 2008-05-08 バーテックス ファーマシューティカルズ インコーポレイテッド Hcvns3−ns4aプロテアーゼの阻害
US7723310B2 (en) 2004-10-18 2010-05-25 Three Rivers Pharmaceuticals, Llc Large dose ribavirin formulations
US20060228333A1 (en) 2004-10-20 2006-10-12 Kye-Hyung Paik Methods for control of tumors and chronic infections by modulating immunologically informed carriers homing to tolerogenic organs or tissues
WO2006043153A2 (en) 2004-10-20 2006-04-27 Michel Xilinas Use of zinc and copper chelators for the treatment of viral diseases
AU2005298412B2 (en) 2004-10-26 2011-06-09 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
MY141025A (en) 2004-10-29 2010-02-25 Vertex Pharma Dose forms
US7592315B2 (en) 2004-11-02 2009-09-22 Schering Corporation Peptide viral entry inhibitors
US20060122127A1 (en) 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
WO2006055711A1 (en) 2004-11-18 2006-05-26 Kent Hann Compositions containing aloe vera isolate and a prebiotic and their therapeutic application
JP2008523082A (ja) 2004-12-09 2008-07-03 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗菌活性および抗癌活性を有するヌクレオチド
TW200633718A (en) 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
EP1674104A1 (en) 2004-12-24 2006-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
US20080161232A1 (en) 2005-01-17 2008-07-03 Jerini Ag C5a Receptor Antagonist
JP2008528698A (ja) 2005-02-03 2008-07-31 インターシア セラピューティクス,インコーポレイティド 埋め込み可能なインターフェロン含有デバイス
WO2006096285A2 (en) 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
WO2006089113A2 (en) 2005-02-18 2006-08-24 Intermune, Inc. Biomarkers for predicting liver fibrosis treatment efficacy
US8232240B2 (en) 2005-02-23 2012-07-31 The Brigham And Women's Hospital, Inc. Inhibitors of enveloped virus infectivity
US20090156545A1 (en) 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
US20060229293A1 (en) 2005-04-06 2006-10-12 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
JP2008538354A (ja) 2005-04-08 2008-10-23 キメリクス,インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
WO2006113431A2 (en) 2005-04-13 2006-10-26 University Of Massachusetts Dual functional oligonucleotides for use as anti-viral agents
US20060241144A1 (en) 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
NZ563909A (en) 2005-05-13 2011-10-28 Virochem Pharma Inc Thiophene derivatives and their use for the treatment or prevention of flavivirus infections
WO2006127482A1 (en) 2005-05-20 2006-11-30 Bioenvision, Inc. Methylene blue therapy of viral disease
EP1881828A4 (en) 2005-05-20 2009-06-03 Valeant Res & Dev TREATMENT OF HEPATITIS C (HCV) USING SUB-THERAPEUTIC DOSES OF RIBAVIRIN
US20060269516A1 (en) 2005-05-26 2006-11-30 Schering Corporation Interferon-IgG fusion
US20080199428A1 (en) 2005-05-31 2008-08-21 Alberti Daniele M Treatment of Liver Diseases in Which Iron Plays a Role in Pathogenesis
US7793040B2 (en) 2005-06-01 2010-09-07 Microsoft Corporation Content addressable memory architecture
WO2006130688A2 (en) 2005-06-02 2006-12-07 Schering Corporation Compounds for inhibiting cathepsin activity
US20070237818A1 (en) 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
US20070232527A1 (en) 2005-06-02 2007-10-04 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
WO2006130552A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
US20060275366A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US20070004635A1 (en) 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
ES2572980T3 (es) 2005-06-02 2016-06-03 Merck Sharp & Dohme Corp. Combinación de inhibidores de la proteasa del VHC con un tensioactivo
WO2006130687A2 (en) 2005-06-02 2006-12-07 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor
US20060281689A1 (en) 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US20060276407A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US20070207949A1 (en) 2005-06-02 2007-09-06 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
WO2006130666A2 (en) 2005-06-02 2006-12-07 Schering Corporation Medicaments and methods combining a hcv protease inhibitor and an akr competitor
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
CA2609343C (en) 2005-06-07 2015-03-31 Yale University Methods of treating cancer and other conditions or disease states using lfmau and ldt
RU2293572C1 (ru) 2005-07-18 2007-02-20 Гюнтер Хаазе Способ лечения хронического вирусного гепатита с генотип-2 с умеренной активностью
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
EP2402331A1 (en) 2005-08-02 2012-01-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP1924596A4 (en) 2005-08-12 2009-07-29 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
DE102005038768A1 (de) 2005-08-16 2007-02-22 Toximed Gmbh Pharmazeutischer Wirkstoff gegen Borreliose
DE602006013492D1 (de) 2005-08-19 2010-05-20 Vertex Pharma Verfahren und zwischenprodukte
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
US7531164B2 (en) 2005-10-21 2009-05-12 Duke University Preventing bacterial or viral infectivity and composition containing infection preventing additive
IE20050723A1 (en) 2005-10-28 2007-05-30 Patrick T Prendergast Anti-mineralocorticoid therapy of infection
WO2007056016A2 (en) 2005-11-02 2007-05-18 Kemia, Inc. Bisamide cytokine inhibitors
RU2306134C2 (ru) 2005-11-07 2007-09-20 Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" Способ базисного лечения хронического вирусного гепатита c
KR20140098867A (ko) 2005-11-11 2014-08-08 버텍스 파마슈티칼스 인코포레이티드 C형 간염 바이러스 변이체
WO2007058384A1 (en) 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
RU2326115C2 (ru) 2005-11-21 2008-06-10 Ефаг АО Соли 1-алкиламино-1-дезоксиполиолов с 9-оксоакридин-10-уксусной кислотой, лекарственные препараты на их основе, применение, способы профилактики и лечения
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
US8293726B2 (en) 2005-12-02 2012-10-23 Vianova Labs, Inc. Treatment of cancer and other diseases
BRPI0619563A2 (pt) 2005-12-09 2011-10-04 Pharmasset Inc nucleosìdeos antivirais
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
WO2007075896A2 (en) 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
RU2306934C1 (ru) 2005-12-28 2007-09-27 ГОУ ВПО Омская Государственная Медицинская Академия Способ лечения больных хроническим вирусным гепатитом c
ES2422556T3 (es) 2006-01-09 2013-09-12 Romark Lab Lc Tratamiento de hepatitis vírica
MD20060037A (ro) 2006-01-24 2007-07-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Metodă de tratament al hepatitei virale acute C
PE20071230A1 (es) 2006-02-09 2008-01-16 Schering Corp Combinaciones y metodos de inhibidores del vhc
JP2009526070A (ja) 2006-02-09 2009-07-16 シェーリング コーポレイション Hcvプロテアーゼ阻害薬とhcvポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法
US8039475B2 (en) 2006-02-27 2011-10-18 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
KR20080112303A (ko) 2006-03-16 2008-12-24 버텍스 파마슈티칼스 인코포레이티드 중수소화 c형 간염 프로테아제 억제제
NZ571934A (en) 2006-03-20 2012-05-25 Vertex Pharma Methods of spray drying formulations of vx-950 (telaprevir)
US20070218138A1 (en) 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
WO2007111866A2 (en) 2006-03-23 2007-10-04 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
WO2007130646A2 (en) 2006-05-04 2007-11-15 The Rockefeller University Hcv coreceptor and methods of use thereof
US20100256217A1 (en) 2006-05-22 2010-10-07 The Trustees Of The University Of Pennsylvania Antiviral inhibition of casein kinase ii
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
CA2654183A1 (en) 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
EP2029730A1 (en) 2006-06-04 2009-03-04 Cellartis AB Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
WO2007146712A2 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
WO2007149382A2 (en) 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in treating hepatitis
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US20080081791A1 (en) 2006-07-06 2008-04-03 Weida Huang Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi
MX2009000236A (es) 2006-07-07 2009-01-23 Gilead Sciences Inc Compuestos de fosfinato antivirales.
EP2041156B1 (en) 2006-07-13 2013-11-20 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008022006A2 (en) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis c virus protease inhibitors
EP2054076A2 (en) 2006-08-21 2009-05-06 United Therapeutics Corporation Combination therapy for treatment of viral infections
CA2659461A1 (en) 2006-08-25 2008-02-28 Wyeth Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
WO2008073165A2 (en) 2006-08-25 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-hcv agents
TW200815384A (en) 2006-08-25 2008-04-01 Viropharma Inc Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
US9216197B2 (en) 2006-09-11 2015-12-22 Biomas Ltd. Topical formulations of tellurium-containing compounds
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
KR20090064453A (ko) 2006-09-14 2009-06-18 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
CA2664935A1 (en) 2006-09-26 2008-04-03 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
CN101600725B (zh) 2006-10-10 2014-11-26 吉利德制药有限责任公司 制备呋喃核糖基嘧啶核苷
US7777395B2 (en) 2006-10-12 2010-08-17 Eastman Kodak Company Continuous drop emitter with reduced stimulation crosstalk
EP2086982B1 (en) 2006-10-27 2018-08-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
NZ576780A (en) 2006-11-15 2011-12-22 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
WO2008143647A2 (en) 2006-11-29 2008-11-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating viral infection
CA2673111A1 (en) 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
RU2336096C1 (ru) 2006-12-14 2008-10-20 ООО Медицинский центр "Столица" Способ лечения гепатита с
RU2345787C2 (ru) 2006-12-25 2009-02-10 Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" Способ лечения хронического вирусного гепатита с
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2679563A1 (en) 2007-01-08 2008-07-17 Phenomix Corporation Macrocyclic hepatitis c protease inhibitors
WO2008089034A2 (en) 2007-01-11 2008-07-24 Kemia, Inc. Cytokine inhibitors
US7645732B2 (en) 2007-01-24 2010-01-12 Board Of Regents, The University Of Texas System Treating hepatitis C virus infection
BRPI0806945A2 (pt) 2007-02-01 2014-05-06 Tibotec Pharm Ltd Formas polimórficas de um inibidor macrocíclico de hcv
TW200838550A (en) 2007-02-09 2008-10-01 Novartis Ag Organic compounds
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
DK2125026T3 (en) 2007-02-21 2014-12-08 Allaccem Inc FORMATIONS BASED ON bridged POLYCYCLIC COMPOUNDS FOR INHIBITION AND RELIEF OF DISEASES
PT2114924E (pt) 2007-02-27 2012-04-03 Vertex Pharma Co-cristais e composições farmacêuticas que compreendem os mesmos
WO2008106167A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
MD3477G2 (ro) 2007-03-21 2008-08-31 Николае БОДРУГ Metodă de tratament al hepatitei virale cronice C
EP2125024B1 (en) 2007-03-23 2013-02-13 TO-BBB Holding B.V. Targeted intracellular delivery of antiviral agents
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2008124384A2 (en) 2007-04-03 2008-10-16 Aegerion Pharmaceuticals, Inc. Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
EP2155257B1 (en) 2007-04-27 2016-10-05 Chimerix, Inc. Methods of reducing nephrotoxicity in subjects administered with nucleoside
US20080269205A1 (en) 2007-04-27 2008-10-30 Ondine International, Ltd. Methods to prevent vertical transmission of infectious diseases
WO2008137779A2 (en) 2007-05-03 2008-11-13 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CN101815533A (zh) 2007-05-04 2010-08-25 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
MX2009012093A (es) 2007-05-10 2010-01-25 Intermune Inc Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c.
JP2010528013A (ja) 2007-05-21 2010-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Vx−950を含む用量形態およびそれらの投与レジメン
RU2348412C1 (ru) 2007-06-01 2009-03-10 Лариса Леонидовна Попова Способ профилактики рецидива хронического вирусного гепатита с после достижения вирусологической ремиссии
WO2008154248A1 (en) 2007-06-06 2008-12-18 Inova Health System Prognostic chronic hepatitis c biomarkers
KR101596524B1 (ko) 2007-06-29 2016-02-22 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
KR20100056479A (ko) 2007-07-25 2010-05-27 바이오렉스 쎄라퓨틱스, 인코포레이티드 제어 방출 인터페론 약물 제품 및 이를 사용한 hcv 감염의 치료
EP2178584A2 (en) 2007-07-26 2010-04-28 Entra Pharmaceuticals Inc. Skin-patch pump comprising a changing-volume electrochemical actuator
EP2194976B1 (en) 2007-08-03 2015-12-09 Biotron Limited Hepatitis C antiviral compositions comprising 5-(1-methylpyrazol-4-yl)2-naphthoylguanidine and 2'-C-methyladenosine or 2'-C-methylcytidine
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US20110166092A1 (en) 2007-08-20 2011-07-07 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
JP5443360B2 (ja) 2007-08-30 2014-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド 共結晶体およびそれを含む医薬組成物
WO2009033183A2 (en) 2007-09-08 2009-03-12 University Of Florida Research Foundation Compounds and methods for treatment of hcv and conditions associated with cd81 binding
US20090076100A1 (en) 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched gsk625433
DK2061513T3 (da) 2007-09-14 2011-11-21 Schering Corp Fremgangsmåde til behandling af patienter med hepatitis C
PT2639226T (pt) 2007-09-17 2016-12-09 Abbvie Bahamas Ltd Pirimidinas anti-infeciosas e suas utilizações
JP5734654B2 (ja) 2007-09-17 2015-06-17 アッヴィ・バハマズ・リミテッド C型肝炎を治療するためのウラシルまたはチミン誘導体
WO2009039135A1 (en) 2007-09-17 2009-03-26 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
JP5715820B2 (ja) 2007-09-18 2015-05-13 スタンフォード ユニバーシティー フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物
US20090082366A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telaprevir
US20090082414A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched viramidine
JP5486744B2 (ja) 2007-10-03 2014-05-07 サベル コーポレーション ムユヨの花、トゲバンレイシの葉、及びウコンの根の抽出物を含む、肝炎を治療するための組成物
US20110270212A1 (en) 2007-10-05 2011-11-03 Medtronic, Inc. Pharmacokinetic control for optimized interferon delivery
JP2011503060A (ja) 2007-11-05 2011-01-27 バーテックス ファーマシューティカルズ インコーポレイテッド Vx−950、peg−ifnおよびリババリンを含むhcv併用治療剤
US20110182858A1 (en) 2007-11-15 2011-07-28 Madaus Gmbh Silibinin component for the treatment of hepatitis
ES2599927T3 (es) 2007-12-21 2017-02-06 F. Hoffmann-La Roche Ag Proceso para la preparación de un macrociclo
CN101951769B (zh) 2007-12-21 2014-12-31 阿维拉制药公司 Hcv蛋白酶抑制剂和其用途
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
EP2234623A4 (en) 2007-12-27 2012-03-28 Epiphany Biosciences ANTIVIRAL CONNECTIONS
WO2009109665A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
JP5283106B2 (ja) 2008-03-14 2013-09-04 国立大学法人 熊本大学 C型肝炎ウイルス阻害剤
US20100009970A1 (en) 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20110045001A1 (en) 2008-03-28 2011-02-24 Biontex Laboratories Gmbh Transfection results of non-viral gene delivery systems by influencing of the innate immune system
US20090257979A1 (en) 2008-04-15 2009-10-15 Intermune, Inc. Novel Inhibitors of Hepatitis C Virus Replication
MX2010011580A (es) 2008-04-23 2010-11-09 Vertex Pharma Tratamiento de infecciones por virus de hepatitis c con telaprevir (vx-950) en pacientes que no responden al tratamiento con interferon-alfa-2a-2b pegilado y ribavirina.
DE102008029669A1 (de) 2008-05-16 2009-11-19 Schlaak, Jörg Friedrich, Prof. Dr. med. Neue Therapeutika für die Hepatitis-Therapie
EP2318031A4 (en) 2008-06-03 2012-09-12 Aethlon Medical Inc IMPROVED METHODS AND DEVICES FOR ANTIVIRAL THERAPY
US20110165121A1 (en) 2008-06-05 2011-07-07 Hausman Diana F Use of pegylated type iii interferons for the treatment of hepatitis c
US20110165119A1 (en) 2008-06-10 2011-07-07 Maria Gloria Beumont Telaprevir dosing regimen
WO2009152589A1 (en) 2008-06-17 2009-12-23 Universidade Federal De Minas Gerais-Ufmg Use of paf receptor for treating infections caused by flaviviridae
KR101313675B1 (ko) 2008-07-22 2013-10-02 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티 에스.알.엘. Hcv ns3 프로테아제 억제제로서의 마크로사이클릭 퀴녹살린 화합물
WO2010011343A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Methods for treating viral disorders
RU2373952C1 (ru) 2008-07-30 2009-11-27 Юрий Михайлович Амбалов Способ лечебного питания больных хроническим гепатитом с, получающих комплексную противовирусную терапию
JP2011530519A (ja) 2008-08-06 2011-12-22 サイクローン・ファーマシューティカルズ・インコーポレイテッド 免疫調節化合物を用いたc型肝炎の治療または予防の方法
WO2010015637A1 (en) * 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
BRPI0916609A2 (pt) 2008-08-07 2015-08-04 Hoffmann La Roche Processo para a preparação de um macrociclo
EP2323631A1 (en) 2008-08-07 2011-05-25 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
WO2010021681A2 (en) 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010020676A1 (en) 2008-08-20 2010-02-25 Vib Vzw The use of topoisomerase type i inhibitors to treat viral infections
JP2012501345A (ja) 2008-08-28 2012-01-19 バーテックス ファーマシューティカルズ インコーポレイテッド Hcv遺伝子型の分析
JP5409636B2 (ja) 2008-08-29 2014-02-05 国立大学法人大阪大学 抗c型肝炎ウイルス組成物
MX2011002312A (es) 2008-09-03 2011-04-26 Vertex Pharma Co-cristales y formulaciones farmaceuticas que comprenden los mismos.
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
BRPI0918513A2 (pt) 2008-09-16 2015-12-01 Boehringer Ingelheim Int formas cristalinas de um derivado de 2-tiazolil-4-quinolinil-óxi, seu sal de sódio, suas composições farmacêuticas e seu uso
CN102159245B (zh) 2008-09-17 2013-07-24 贝林格尔.英格海姆国际有限公司 Hcv ns3蛋白酶抑制剂与干扰素和利巴韦林的组合
WO2010031832A2 (en) 2008-09-18 2010-03-25 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
CA2738477A1 (en) 2008-09-24 2010-04-01 Robert S. Kauffman Therapeutic regimen comprising peg-interferon, ribavirin and vx-950 for the treatment of hepatitis
EP2334379A2 (en) 2008-09-26 2011-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Host cell kinases as targets for antiviral therapies against hcv infection
JPWO2010038796A1 (ja) 2008-09-30 2012-03-01 持田製薬株式会社 C型肝炎治療剤
WO2010039801A2 (en) 2008-10-02 2010-04-08 The J. David Gladstone Institutes Methods of treating hepatitis c virus infection
KR20110065568A (ko) 2008-10-08 2011-06-15 샬롯테-맥클렌버그 하스피털 오쏘러티 두잉 비지니스 에즈 카롤리나스 메디컬 센터 마이크로rna-196의 과발현을 이용한 간염 c 바이러스 감염 치료
CA2740728A1 (en) 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
WO2010049438A2 (en) 2008-10-30 2010-05-06 Innate Pharma Improved methods of using phosphoantigens for the treatment of diseases
EP2358439A1 (en) 2008-11-05 2011-08-24 Vertex Pharmaceuticals Incorporated Methods for treating hepatitis c virus infection
EA022272B1 (ru) 2008-11-21 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтическая композиция эффективного ингибитора всг для перорального введения
AU2009324643B2 (en) 2008-12-10 2014-08-28 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8664188B2 (en) 2008-12-11 2014-03-04 Xiangxue Group (Hong Kong) Company Limited siRNA compositions and methods for potently inhibiting viral infection
CA2745284A1 (en) 2008-12-18 2010-06-24 F. Hoffmann-La Roche Ag Biomarkers for hcv treatment response
AU2009329917B2 (en) 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
ES2567047T3 (es) 2008-12-23 2016-04-19 Abbvie Inc. Derivados de pirimidina anti-virales
WO2010076788A2 (en) 2008-12-29 2010-07-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
US8840934B2 (en) 2009-01-02 2014-09-23 Rainbow Pharmaceutical Sa Uses of ammonium chloride
JP2012514657A (ja) 2009-01-09 2012-06-28 ユニバーシテイ・カレツジ・オブ・カーデイフ・コンサルタンツ・リミテツド ウィルス感染を治療するためのグアノシンヌクレオシド化合物のホスホルアミダート誘導体
RU2398582C1 (ru) 2009-01-19 2010-09-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.М. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ лечения хронического вирусного гепатита с 1-генотипа с умеренной активностью и репликативностью
EP2396028A2 (en) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010101649A2 (en) 2009-03-05 2010-09-10 Pablo Gastaminza Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
BRPI1013227A2 (pt) 2009-03-05 2016-03-29 Ascendis Pharma As pró-fármacos transportadores de interferon alfa
RU2571662C2 (ru) 2009-03-25 2015-12-20 Эббви Инк. Противовирусные соединения и их применения
ES2413080T3 (es) 2009-03-25 2013-07-15 Abbvie Inc. Compuestos antivirales y usos de los mismos
JP5734956B2 (ja) 2009-04-15 2015-06-17 アッヴィ・インコーポレイテッド 抗ウィルス化合物
US20120115918A1 (en) 2009-04-15 2012-05-10 Abbott Laboratories Anti-Viral Compounds
JP5773535B2 (ja) 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S インターフェロンに非応答性のhcv患者の治療のための医薬組成物
CN105233249A (zh) 2009-04-25 2016-01-13 弗·哈夫曼-拉罗切有限公司 改善药物动力学的方法
MX363732B (es) 2009-05-13 2019-04-01 Gilead Pharmasset Llc Star Compuestos antivirales.
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
AU2010249379B2 (en) 2009-05-21 2013-09-26 Merck Sharp & Dohme Corp. Genetic markers associated with interferon-alpha response
AR077060A1 (es) 2009-06-11 2011-07-27 Abbott Lab Compuestos antivirales
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
AR077139A1 (es) 2009-06-23 2011-08-03 Gilead Sciences Inc Composiciones farmaceuticas utiles para tratar el vch
WO2010151472A1 (en) 2009-06-23 2010-12-29 Gilead Sciences, Inc. Combination of a ns5b polymerase inhibitor and a hcv ns3 protease inhibitor for the treatment of hcv
WO2010151487A1 (en) 2009-06-23 2010-12-29 Gilead Sciences, Inc. Combination of telaprevir with 5- ({6- [2,4-bis (trifluoromethyl) phenyl] pyridazin-3 -yl)methyl) -2- (2 -fluorophenyl) -5h- imidazo [4, 5-c]pyridine for the treatment of hcv
CA2968113C (en) 2009-06-26 2019-05-14 Romark Laboratories L.C. Compounds and methods for treating influenza
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
WO2011005646A2 (en) 2009-07-07 2011-01-13 Boehringer Ingelheim International Gmbh Pharmaceutical composition for a hepatitis c viral protease inhibitor
RU2400229C1 (ru) 2009-07-13 2010-09-27 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" СПОСОБ ЛЕЧЕНИЯ БОЛЬНЫХ ХРОНИЧЕСКИМ ВИРУСНЫМ ГЕПАТИТОМ С, ГЕНОТИПОМ 3а
WO2011009961A1 (en) 2009-07-24 2011-01-27 Virologik Gmbh Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
JP2013500713A (ja) 2009-07-31 2013-01-10 サントル オスピタリエ ウニヴェルシテール ヴォドア Hcv感染患者においてc型肝炎の転帰を診断又は予測する方法
CN102470158A (zh) 2009-08-27 2012-05-23 默沙东公司 制备丙型肝炎病毒的蛋白酶抑制剂的工艺方法
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
TW201116540A (en) 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US9174988B2 (en) 2009-10-27 2015-11-03 Trustees Of Boston University Small molecule inhibitors of hepatitis C virus
WO2011056650A2 (en) 2009-10-27 2011-05-12 Michael Zasloff Methods and compositions for treating and preventing viral infections
AU2010313497B2 (en) 2009-10-30 2013-08-01 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
EP2499263A2 (en) 2009-11-09 2012-09-19 Merck Sharp & Dohme Corp. Markers associated with ribavirin-induced anemia
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
US8623416B2 (en) 2009-11-25 2014-01-07 Michael Zasloff Formulations comprising aminosterols
JP5536229B2 (ja) 2009-12-18 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Hcv併用療法
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
SG181904A1 (en) 2009-12-23 2012-07-30 Novartis Ag Lipids, lipid compositions, and methods of using them
RU2424794C1 (ru) 2009-12-30 2011-07-27 Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО УГМА Росздрава) Способ лечения врожденного гепатита с у детей первого года жизни
EP2528605A1 (en) 2010-01-29 2012-12-05 Vertex Pharmaceuticals Incorporated Therapies for treating hepatitis c virus infection
CN103118681B (zh) 2010-03-10 2015-02-18 艾伯维巴哈马有限公司 固体组合物
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
SMT201700412T1 (it) 2010-03-31 2017-11-15 Gilead Pharmasset Llc Procedimento per la cristallizzazione di (s)-isopropil 2-(((s)-(perfluorofenossi)(fenossi)fosforil)ammino)propanoato
TW201211046A (en) 2010-06-07 2012-03-16 Enanta Pharm Inc Macrocyclic hepatitis C serine protease inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
AR084393A1 (es) 2010-06-10 2013-05-15 Gilead Sciences Inc Metodos para tratar el virus de la hepatitis c, composicion, uso, combinacion, kit y uno o mas compuestos anti vhc
US8592372B2 (en) 2010-06-29 2013-11-26 King Saud University Liver Disease Pharmaceutical composition and method of use to improve organ function
RU2429877C1 (ru) 2010-06-30 2011-09-27 Общество с ограниченной ответственностью "ИНГИЛС" Способ лечения хронического вирусного гепатита с
AR082215A1 (es) 2010-07-14 2012-11-21 Vertex Pharma Composicion farmaceutica agradable al paladar
MX2013000623A (es) 2010-07-16 2013-06-13 Abbvie Inc Proceso para la preparación de compuestos antivirales.
JP2013535469A (ja) 2010-07-30 2013-09-12 メルク・シャープ・エンド・ドーム・コーポレイション Cyp3a薬物代謝の阻害
US20120196272A1 (en) 2010-08-05 2012-08-02 Roche Molecular Systems, Inc. Prediction of HCV Viral Kinetics in Interferon-Free Treatment
US20120196794A1 (en) 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
EP2621501A4 (en) 2010-09-29 2014-04-09 Merck Sharp & Dohme POLYCYCLIC HETEROCYCLUS DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
PE20131397A1 (es) 2010-09-30 2014-01-04 Boehringer Ingelheim Int Terapia de combinacion para tratar infeccion por hcv
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
TWI451439B (zh) 2010-12-10 2014-09-01 Phison Electronics Corp 記憶體儲存裝置、其記憶體控制器與資料寫入方法
EP2651885A1 (en) 2010-12-16 2013-10-23 Abbvie Inc. Anti-viral compounds
TW201701876A (zh) 2010-12-20 2017-01-16 吉李德科學股份有限公司 治療c型肝炎病毒(hcv)之方法
CA2822357A1 (en) 2010-12-22 2012-06-28 Abbvie Inc. Hepatitis c inhibitors and uses thereof
WO2012092411A2 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
JP2014510155A (ja) 2011-04-06 2014-04-24 ザ トラスティーズ オブ プリンストン ユニバーシティ 抗ウイルス組み合わせ治療薬
JP2014522814A (ja) 2011-06-23 2014-09-08 ステラ・アンパルトセルスカブ Hcv併用療法
KR20140058536A (ko) 2011-06-30 2014-05-14 스텔라 에이피에스 Hcv 조합 치료
JP2014520772A (ja) 2011-06-30 2014-08-25 ステラ・アンパルトセルスカブ Hcv併用療法
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013025975A1 (en) 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
PH12014500386A1 (en) 2011-08-24 2019-10-07 Glaxosmithkline Llc Combination treatment for hepatitis c
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
US8575119B2 (en) * 2011-09-23 2013-11-05 Enanta Pharmaceuticals, Inc. 2′-chloroacetylenyl substituted nucleoside derivatives
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
PT107924A (pt) 2011-10-21 2014-12-03 Abbvie Inc Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
JP2015513520A (ja) 2011-10-31 2015-05-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. ウイルス疾患の治療に有用な組成物
US20130137084A1 (en) 2011-11-28 2013-05-30 Roche Molecular Systems, Inc. Single Nucleotide Polymorphism on Chromosome 15 That Predicts HCV Treatment Responses
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013096680A1 (en) * 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
EP2890704B1 (en) * 2012-08-31 2018-02-28 Novartis AG 2'-ethynyl nucleoside derivatives for treatment of viral infections
HRP20191939T1 (hr) 2012-09-18 2020-01-10 Abbvie Inc. Postupci za liječenje hepatitisa c
AU2013318311A1 (en) 2012-09-18 2015-04-02 Abbvie Inc. Methods for treating hepatitis C
WO2014078463A1 (en) 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. 2 -alkynyl substituted nucleoside derivatives for treating viral diseases
US9598457B2 (en) * 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2935303B1 (en) * 2012-12-21 2021-02-17 Janssen BioPharma, Inc. 4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv
CN108187056A (zh) 2013-03-14 2018-06-22 艾伯维公司 用于治疗hcv患者的直接作用的抗病毒剂和利巴韦林的组合
HRP20171036T1 (hr) 2013-03-14 2017-10-06 Abbvie Inc. Kombinacija dvaju antiviralnih sredstava za liječenje hepatitisa c
HK1224229A1 (zh) * 2013-06-26 2017-08-18 Alios Biopharma, Inc. 取代的核苷,核苷酸及其类似物
US10023626B2 (en) * 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
AU2014331863C1 (en) * 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015095572A1 (en) 2013-12-19 2015-06-25 Abbvie Inc. Methods for treating liver transplant recipients
EP3160475B1 (en) * 2014-06-24 2024-01-03 Janssen Pharmaceuticals, Inc. Substituted nucleosides and nucleotides to treat filoviridae infections
US9603864B2 (en) * 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US20160016986A1 (en) * 2014-07-21 2016-01-21 Milind Deshpande Stabilized nucleotides for medical treatment
MA41441A (fr) * 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
US9980865B2 (en) * 2015-03-30 2018-05-29 Christopher Miranda Elevating wheelchair
CA3022119A1 (en) * 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Similar Documents

Publication Publication Date Title
JP2022106920A5 (OSRAM)
JP2019515930A5 (OSRAM)
HRP20220911T1 (hr) Sastav nukleotida i nukleozida i njihova uporaba
JP2019525905A5 (OSRAM)
KR102248165B1 (ko) N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
IL298529A (en) Inhibitors of cysteine proteases and methods of use thereof
TW202317144A (zh) 口服生物可利用的核苷類似物
JP2014515377A5 (OSRAM)
CA2498572A1 (en) Macrocyclic peptides active against the hepatitis c virus
JP2013537905A5 (OSRAM)
JP2013532725A5 (OSRAM)
IL207468A (en) HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections
JP2013514359A5 (OSRAM)
JP2012504132A5 (OSRAM)
JP2012504129A5 (OSRAM)
JP2012528161A5 (OSRAM)
JP2012528892A5 (OSRAM)
JP2015535853A5 (OSRAM)
JP2012511004A5 (OSRAM)
JP2014522809A5 (OSRAM)
JPWO2021159044A5 (OSRAM)
JP2017503005A5 (OSRAM)
US20250228882A1 (en) Orally-bioavailable nucleoside analogs
IL273990B1 (en) Broad spectrum antiviral compositions and methods
JP2011502998A5 (OSRAM)